ArticleBMC infectious diseases2026
Clinical and microbiological characteristics of polymicrobial bloodstream infections in hematologic malignancy patients: a cross-sectional study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Complementary Utility of Metagenomic Next-Generation Sequencing and Blood Culture for Bloodstream Infections: Insights into Pathogen-Specific Inflammatory and Coagulation Profiles.Infection and drug resistance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with hematological malignancies experience severe immune dysfunction due to the impact of intensive chemotherapy and the impairment of hematopoietic cells. This condition places them at high risk for infectious complications, including bloodstream infections (BSIs), which are associated with increased morbidity and mortality. Polymicrobial bloodstream infections (PBSIs), involving multiple microorganisms, represent a critical clinical condition with high mortality rates in this population. This study aimed to investigate the risk factors for poor clinical outcomes associated with PBSIs in patients with severe immunodeficiency due to hematological malignancies and to propose potential solutions. A retrospective review was conducted on the medical records of patients diagnosed with bloodstream infections at Muğla Education and Research Hospital between 2017 and 2024. Data on demographics, laboratory results, microbiological isolates, antibiotic susceptibility profiles, and mortality outcomes were analyzed. High-risk conditions for PBSI were identified. PBSI was defined as the isolation of two or more bacterial species from blood cultures within 72 h of infection onset. A total of 108 patients were included, of whom 21 (19.4%) were diagnosed with PBSI. The most common pathogens were coagulase-negative staphylococci, Klebsiella spp., and Pseudomonas aeruginosa. Multidrug-resistant (MDR) organisms were identified in 58.3% of cases, and the mortality rate in PBSI patients was 57.1%. Risk factors for mortality included intensive care unit admission, mechanical ventilation, parenteral nutrition, renal failure, and concurrent pneumonia. PBSIs are a significant cause of morbidity and mortality in patients with hematological malignancies undergoing chemotherapy. To mitigate the effects of identified risk factors, measures such as avoiding unnecessary intensive care admissions, minimizing catheter and mechanical ventilation use, prioritizing enteral over parenteral nutrition, and initiating broad-spectrum antibiotics promptly are recommended. Multicenter, randomized, prospective studies are essential to optimize treatment strategies and reduce PBSI-associated mortality in this vulnerable patient group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.